FDA accepted for Priority Review the BLA for V114, Merckï¾’s investigational 15-valent pneumococcal conjugate vaccine
On Jan. 12, 2021, Merck announced the FDA accepted for priority review a Biologics License Application (BLA) for…
Abbott announced fulfillment of Federal government purchase of 150 million BinaxNOWï¾™ COVID-19 Rapid Tests
On Jan. 12, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
Global scientists doubled down on SARS-CoV-2 variants research
On Jan. 12, 2021, the WHO announced that global scientists were intensifying research into COVID-19 to expand its…
UC Berkeley scientists mapped coronavirus protein linked to disease severity
On Jan. 12, 2021, UC Berkeley HIV researchers announced that they had determined the atomic structure of a…
Regeneron announced US Government sgreement to purchase additional COVID-19 antibody cocktail doses
On Jan. 12, 2021, Regeneron announced that the U.S. Department of Health and Human Services (HHS) and the…
Rocheï¾’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluzaï¾® (baloxavir marboxil) for the…
CureVac’s COVID-19 caccine aandidate, CVnCoV, demonstrated efficient protection of non-human primates
On Jan. 11, 2021, CureVac announced the publication of preclinical data demonstrating the induction of robust antibody and…
Abbott received CE Mark for its COVID-19 IgG quantitative antibody blood test
On Jan. 11, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
FDA conditionally approved first oral tablet to treat lymphoma in dogs
On Jan. 11, 2021, the FDA conditionally approved Anivive Lifesciences’ Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma,…
FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editing
On Jan. 11, 2021, Editas Medicine announced the FDA had cleared the initiation of the safety phase of…
Humanigen announced CRADA agreement with US government to develop lenzilumab for COVID-19
On Jan. 10, 2021, Humanigen announced that they were partnering to make lenzilumab available to hospitalized and hypoxic…
FDA issued alert regarding SARS-CoV-2 viral mutation to health care providers and clinical laboratory staff
On Jan. 8, 2021, the FDA alerted clinical laboratory staff and health care providers that it was monitoring…
In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…
PerkinElmer announced the acquisition of Oxford Immunotec for $591 million in cash
On Jan. 7, 2021, PerkinElmer and Oxford Immunotec announce an agreement under which PerkinElmer acquired Oxford Immunotec for…
Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
On Jan. 7, 2021, Twist Bioscience announced it will supply the U.S. Centers for Disease Control and Prevention…
Oragenics entered into material transfer agreement with adjuvance technologies for COVID-19 vaccine adjuvant
On Jan. 7, 2021, Oragenics announced entering into a material transfer agreement with Adjuvance Technologies for use of…
Labcorp awarded CDC contract to study variants of COVID-19 virus and improve public health response
On Jan. 7, 2021, LabCorp announced that it had been awarded a contract from the Centers for Disease…
BioNTech published data on novel mRNA vaccine approach to treat autoimmune diseases in Science
On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune…
HHS announced $22 billion in funding to support expanded testing, vaccination distribution
On Jan. 6, 2021, the U.S. Department of Health and Human Services (HHS) announced the Centers for Disease…
CureVac and Bayer joined forces on COVID-19 vaccine candidate CVnCoV
On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical…
Large clinical trial tested combination monoclonal antibody therapy for mild/moderate COVID-19
On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3…
AIM ImmunoTech announced first COVID-19-induced chronic fatigue ﾓLong Haulerﾔ patient dosed with Ampligen
On Jan. 5, 2021, AIM ImmunoTech announced that the active AMP-511 Expanded Access Program (EAP) had dosed its…
FDA announced statement on authorized dosing schedules for COVID-19 vaccines
On Jan. 4, 2021, the FDA announced that the two different mRNA vaccines were shown remarkable effectiveness of…
Audrey Winkelsas researched SMA through the NIH Oxford-Cambridge Scholars Program
On Jan. 4, 2021, Audrey Winkelsas, a 2015 NIH Oxford-Cambridge Scholars Program doctoral student with spinal muscle atrophy…
Theophrastus wrote of Greeks rotating their staple crops to enhance soil fertility
Greek philosopher Theophrastus (371-287 BCE), the “Father of Botany” wrote of Greeks rotating their staple crops with broad…
Bausch Health’s DEXAVEN received new indication in Poland to treat patients with SARS-CoV-2
On Dec. 30, 2020, Bausch Health announced that the Office for Registration of Medicinal Products, Medical Devices and…
NIH study uncovered blood vessel damage and inflammation in COVID-19 patientsï¾’ brains but no infection
On Dec. 30, 2020, the NIH researchers announced that an in-depth study of how COVID-19 affects a patientï¾’s…
UK medicines regulator approved Oxford University/AstraZeneca COVID-19 vaccine
On Dec. 30, 2020, the COVID-19 vaccine developed by Oxford University/AstraZeneca was given regulatory approval by the UK…
Emergent and Mount Sinai Health System announced clinical program to evuate COVID-HIG product candidate
On Dec. 29, 2020, Emergent BioSolutions and Mount Sinai Health System announced initiation of the clinical program to…
Regeneron announced encouraging data from COVID-19 antibody cocktail trial in hospitalized patient
On Dec. 29, 2020, Regeneron announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the…